Topcon (7732) Q1 2025 earnings summary

Executive summary

• Q1 FY2024 consolidated net sales were ¥51.4B, up 3% year-over-year, but operating income dropped 60% to ¥0.7B due to increased fixed costs and growth investments.

• Net income was negative at -¥1.0B, compared to -¥0.2B in the same quarter last year.

• Market conditions deteriorated versus the original forecast, but structural reforms delivered planned fixed cost reductions.

Financial highlights

• Gross profit rose 4% year-over-year to ¥27.6B, with a gross profit ratio of 53.6%.

• SGA expenses increased 9% to ¥26.9B, contributing to the sharp decline in operating income.

• Ordinary income was -¥0.4B, down from ¥1.8B year-over-year.

• Extraordinary losses were eliminated compared to the previous year.

• FX effects negatively impacted results.

Outlook and guidance

• FY2024 full-year guidance remains unchanged: net sales ¥230.0B (+6%), operating income ¥18.0B (+61%), net income ¥9.5B (+92%).

• ROE expected to rise to 9% from 5% last year; dividend maintained at ¥42 per share.

• Positioning Business targets ¥147.0B sales (+5%) and ¥16.5B operating income (+81%).

• Eye Care Business targets ¥82.0B sales (+9%) and ¥7.5B operating income (+12%).

• Positioning Business aims to boost demand and profitability via new products and structural reforms.